279 related articles for article (PubMed ID: 36040329)
1. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome.
Abi-Jaoude E; Bhikram T; Parveen F; Levenbach J; Lafreniere-Roula M; Sandor P
Cannabis Cannabinoid Res; 2023 Oct; 8(5):835-845. PubMed ID: 36040329
[No Abstract] [Full Text] [Related]
2. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
3. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
Müller-Vahl KR; Schneider U; Prevedel H; Theloe K; Kolbe H; Daldrup T; Emrich HM
J Clin Psychiatry; 2003 Apr; 64(4):459-65. PubMed ID: 12716250
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.
Mosley PE; Webb L; Suraev A; Hingston L; Turnbull T; Foster K; Ballard E; Gomes L; Mohan A; Sachdev PS; Kevin R; Gordon R; Benson M; McGregor IS
NEJM Evid; 2023 Sep; 2(9):EVIDoa2300012. PubMed ID: 38320199
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
7. The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders.
Jakubovski E; Pisarenko A; Fremer C; Haas M; May M; Schumacher C; Schindler C; Häckl S; Aguirre Davila L; Koch A; Brunnauer A; Cimpianu CL; Lutz B; Bindila L; Müller-Vahl K
Front Psychiatry; 2020; 11():575826. PubMed ID: 33324255
[No Abstract] [Full Text] [Related]
8. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
[TBL] [Abstract][Full Text] [Related]
9. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
10. Different responses of repetitive behaviours in juvenile and young adult mice to Δ
Gorberg V; McCaffery P; Anavi-Goffer S
Br J Pharmacol; 2021 Feb; 178(3):614-625. PubMed ID: 33125731
[TBL] [Abstract][Full Text] [Related]
11. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
13. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
14. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
15. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
Müller-Vahl KR; Koblenz A; Jöbges M; Kolbe H; Emrich HM; Schneider U
Pharmacopsychiatry; 2001 Jan; 34(1):19-24. PubMed ID: 11229617
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
[TBL] [Abstract][Full Text] [Related]
17. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study.
Chester LA; Englund A; Chesney E; Oliver D; Wilson J; Sovi S; Dickens AM; Oresic M; Linderman T; Hodsoll J; Minichino A; Strang J; Murray RM; Freeman TP; McGuire P
Cannabis Cannabinoid Res; 2024 Feb; 9(1):188-198. PubMed ID: 36493386
[No Abstract] [Full Text] [Related]
18. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
19. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.
Englund A; Oliver D; Chesney E; Chester L; Wilson J; Sovi S; De Micheli A; Hodsoll J; Fusar-Poli P; Strang J; Murray RM; Freeman TP; McGuire P
Neuropsychopharmacology; 2023 May; 48(6):869-876. PubMed ID: 36380220
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
